CN1305379A - 治疗方法 - Google Patents

治疗方法 Download PDF

Info

Publication number
CN1305379A
CN1305379A CN99807465A CN99807465A CN1305379A CN 1305379 A CN1305379 A CN 1305379A CN 99807465 A CN99807465 A CN 99807465A CN 99807465 A CN99807465 A CN 99807465A CN 1305379 A CN1305379 A CN 1305379A
Authority
CN
China
Prior art keywords
paroxetine
core
smoking
pharmaceutically acceptable
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99807465A
Other languages
English (en)
Chinese (zh)
Inventor
M·X·斯泰纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1305379A publication Critical patent/CN1305379A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN99807465A 1998-06-16 1999-06-16 治疗方法 Pending CN1305379A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9812941.4 1998-06-16
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment

Publications (1)

Publication Number Publication Date
CN1305379A true CN1305379A (zh) 2001-07-25

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99807465A Pending CN1305379A (zh) 1998-06-16 1999-06-16 治疗方法

Country Status (20)

Country Link
EP (1) EP1087766A4 (cs)
JP (1) JP2002518330A (cs)
KR (1) KR20010052895A (cs)
CN (1) CN1305379A (cs)
AP (1) AP2000002002A0 (cs)
AU (1) AU740749B2 (cs)
BG (1) BG105127A (cs)
BR (1) BR9911150A (cs)
CA (1) CA2335236A1 (cs)
CZ (1) CZ20004698A3 (cs)
EA (1) EA003584B1 (cs)
GB (1) GB9812941D0 (cs)
HU (1) HUP0102507A3 (cs)
IL (1) IL139943A0 (cs)
NO (1) NO20006383D0 (cs)
NZ (1) NZ508532A (cs)
PL (1) PL345261A1 (cs)
SK (1) SK19192000A3 (cs)
WO (1) WO1999065491A1 (cs)
ZA (1) ZA200007396B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418038A1 (en) * 2000-08-28 2002-03-07 Synthon B.V. Paroxetine compositions and processes for making the same
IL162666A0 (en) 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Also Published As

Publication number Publication date
WO1999065491A1 (en) 1999-12-23
EP1087766A1 (en) 2001-04-04
IL139943A0 (en) 2002-02-10
CA2335236A1 (en) 1999-12-23
JP2002518330A (ja) 2002-06-25
EP1087766A4 (en) 2001-11-21
HUP0102507A2 (hu) 2002-05-29
EA003584B1 (ru) 2003-06-26
BG105127A (en) 2001-11-30
PL345261A1 (en) 2001-12-03
NZ508532A (en) 2003-08-29
SK19192000A3 (sk) 2001-05-10
EA200100041A1 (ru) 2001-06-25
ZA200007396B (en) 2002-02-27
AU740749B2 (en) 2001-11-15
NO20006383L (no) 2000-12-14
AU4688599A (en) 2000-01-05
GB9812941D0 (en) 1998-08-12
HUP0102507A3 (en) 2003-12-29
BR9911150A (pt) 2001-03-06
AP2000002002A0 (en) 2000-12-31
CZ20004698A3 (cs) 2002-02-13
KR20010052895A (ko) 2001-06-25
NO20006383D0 (no) 2000-12-14

Similar Documents

Publication Publication Date Title
CN1142780C (zh) 药用组合物
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
CN1142783C (zh) 用于治疗高危葡萄糖耐量降低的药剂
CN1323664C (zh) 雷诺嗪缓释制剂
CN1236770C (zh) 胃酸分泌抑制组合物
CN1201822C (zh) 含有拟交感神经胺盐的不适合非法使用的组合物
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
CN1134108A (zh) 用于控释的新颗粒及含有该颗粒的药物制剂
CN1638771A (zh) 3－[(2－{[4－(己氧羰基氨基－亚氨基－甲基)－苯基氨基]－甲基}－1－甲基－1h－苯并咪唑－5－羰基）－吡啶－2－基－氨基]－丙酸乙酯及其盐的口服施用的投药剂型
CN1646103A (zh) 高药物载荷片剂
CN1321088A (zh) 雷诺嗪持续释放制剂
JP2017061561A (ja) ニタゾキサニドの制御放出医薬配合物
CN1562024A (zh) 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂
CN1183049A (zh) 含质子泵抑制剂和促运动剂的口服药物剂型
US20130059002A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
CN101076321A (zh) 治疗失眠的药物的时间延迟剂型
CN1956707A (zh) 包含n－(2－(2－苯二酰亚氨基乙氧基)－乙酰基)－l－丙氨酰基－d－谷氨酸(lk－423)的耐胃酸的药物剂型
US6300343B1 (en) Method of treatment
CN1610548A (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
CN1305379A (zh) 治疗方法
CN1839846A (zh) 左氧氟沙星缓释微丸、其制备方法及其用途
CN1188131C (zh) 苯二氮卓类药物口服脉冲释药系统及其制备方法
CN1889948A (zh) 他汀用于治疗代谢综合征的用途
CN1291715C (zh) 含有依匹斯汀及假麻黄碱的新药物组合物
JP2004035535A (ja) 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication